HLA-A and myeloid sarcoma: Healy et al. reported that HLA-A*02 and HLA B*44 alleles both reduce susceptibility to MS; however, only HLA-B*44 seems to influence disease course, preserving brain volume and reducing the burden of T2 hyperintense lesions in subjects with MS [34].